Merck KGaA (FRA:MRK) received a €115.00 ($133.72) target price from stock analysts at UBS Group in a research note issued on Thursday, www.boersen-zeitung.de reports. The firm presently has a “buy” rating on the healthcare company’s stock. UBS Group’s price target suggests a potential upside of 23.36% from the company’s current price.
A number of other equities analysts also recently commented on the stock. Nord/LB set a €80.00 ($93.02) target price on shares of Merck KGaA and gave the stock a “sell” rating in a research note on Thursday, January 24th. Goldman Sachs Group set a €95.00 ($110.47) target price on shares of Merck KGaA and gave the stock a “neutral” rating in a research note on Tuesday, February 12th. Credit Suisse Group set a €110.00 ($127.91) target price on shares of Merck KGaA and gave the stock a “buy” rating in a research note on Thursday, November 15th. JPMorgan Chase & Co. set a €100.00 ($116.28) target price on shares of Merck KGaA and gave the stock a “neutral” rating in a research note on Tuesday, January 8th. Finally, Oddo Bhf set a €100.00 ($116.28) price target on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Wednesday, November 14th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of €98.90 ($115.00).
Shares of MRK stock opened at €93.22 ($108.40) on Thursday. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Recommended Story: Swap
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.